Mabion S.A.
$7.52▲ 0.40%(+$0.03)
TickerSpark Score
35/100
▌ Weak
65
Valuation
20
Profitability
10
Growth
52
Health
30
Momentum
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a MAB.WA research report →
52-Week Range24% of range
Low
$6.70
Current
$7.52
High
$10.16
Company Overviewwww.mabion.eu
About the company
Mabion S. A. is a Polish biopharmaceutical firm dedicated to pioneering the development of biological drugs, primarily leveraging monoclonal antibody technology.
- CEO
- Krzysztof Kaczmarczyk
- IPO
- 2010
- Employees
- 206
- HQ
- Konstantynów Lódzki, PL
Price Chart
-22.47% · this period
Valuation
- Market Cap
- $121.54M
- P/E
- -2.13
- P/S
- 6.90
- P/B
- 3.11
- EV/EBITDA
- -3.63
- Div Yield
- 0.00%
Profitability
- Gross Margin
- -82.10%
- Op Margin
- -272.67%
- Net Margin
- -324.20%
- ROE
- -95.68%
- ROIC
- -67.78%
Growth & Income
- Revenue
- $15.76M · -77.17%
- Net Income
- $-62,614,000 · -888.54%
- EPS
- $-3.87 · -892.31%
- Op Income
- $-52,759,000
- FCF YoY
- -261.63%
Performance & Tape
- 52W High
- $10.16
- 52W Low
- $6.70
- 50D MA
- $7.68
- 200D MA
- $8.08
- Beta
- 0.40
- Avg Volume
- 34.30K
Get TickerSpark's AI analysis on MAB.WA
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Coverage · MAB.WA
Our MAB.WA coverage
Recent articles, reports, and earnings notes.
On-Demand Research
No research on MAB.WA yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate MAB.WA report →Internal Compare
Similar companies
Peers in the same neighborhood.